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ABSTRACT	Information	about	the	solid-state	properties	of	etifoxine	has	been	lacking,	even	if	the	active	pharmaceutical	ingredient	has	been	used	for	 its	anxiolytic	properties	 for	decennia.	The	crystal	 structure	of	 the	 racemic	compound	possesses	a	monoclinic	space	group	P21/n	with	cell	parameters	a	=	8.489(2)	Å,	b	=	17.674(2)	Å,	c	=	20.883(3)	Å, b	=	98.860(10)°	and	a	unit-cell	volume	of	3095.8(9)	Å3	at	293	K.	The	unit	cell	contains	8	molecules,	while	2	independent	molecules	with	different	conformations	are	present	in	the	asymmetric	unit.	The	density	of	the	crystal	is	1.291	g/cm3	and	its	melting	point	was	found	at	362.6	±0.3	K	with	a	melting	enthalpy	of	85.6	±3.0	J	g-1.	Its	thermal	expansion	in	the	liquid	and	the	solid	state	and	the	change	in	volume	on	melting	and	between	the	vitreous	state	and	the	crystalline	solid	have	been	studied.	The	results	confirm	the	tendency	of	small	organic	molecules	to	increase	about	11%	in	volume	on	melting,	while	the	volume	difference	between	the	glass	and	the	crystal	at	the	glass	transition	temperature	is	about	half	this	value	at	6%.	These	values	can	be	used	in	the	construction	of	phase	diagrams	in	the	case	that	the	experimental	data	for	a	given	system	is	incomplete.	
Keywords:	active	pharmaceutical	ingredient,	thermodynamic	properties,	crystallographic	properties,	solid	state,	phase	diagram,	melting,	vitreous	state	INTRODUCTION	The	active	pharmaceutical	ingredient	(API)	etifoxine	(Figure	1)	was	developed	about	60	years	ago	and	the	racemic	compound	is	marketed	for	its	anxiolytic	properties.1-3	Its	anxiolytic	effect	is	comparable	with	that	of	some	benzodiazepine	drugs	such	as	lorazepam,	but	it	has	less	side	effects.2,	4,	5	Etifoxine	is	prescribed	in	France	and	in	some	other	countries,	considering	this	drug	as	a	safe	alternative	to	benzodiazepine	drugs.	Although	 it	 has	 been	 marketed	 for	 years,	 structural	 and	 thermodynamic	 solid-state	 studies	 remain	inadequate,	even	if	its	unit	cell	has	previously	been	published	in	the	CSD.6,	7	The	main	purpose	of	the	present	study	was	to	provide	this	data	and	the	results	are	presented	hereafter.	
	
Figure	1.	Chemical	formula	of	racemic	etifoxine.	C17H17ClN2O,	M	=	300.786	g	mol-1.	IUPAC	name:	6-chloro-N-ethyl-4-methyl-4-phenyl-3,1-benzoxazin-2-amine.	The	stereogenic	center	is	indicated	by	an	asterisk.		Besides	the	API-specific	use	of	the	properties	determined	in	this	paper,	the	data	also	contribute	to	statistical	information	that	can	be	used	to	study	the	general	solid-state	behavior	of	small	organic	molecules,	which	make	up	a	large	part	of	the	present-day	marketed	oral	drugs.	In	this	light,	the	thermal	expansion	of	the	solid	and	of	the	liquid	of	etifoxine	will	be	compared	to	that	of	other	APIs.	Moreover,	the	experimental	thermal	expansion	will	be	used	to	determine	the	change	in	volume	of	the	compound	on	melting	and	the	difference	in	volume	between	the	crystalline	solid	and	the	vitreous	state.	This	kind	of	data	appears	to	be	relatively	constant	among	small	organic	molecules	and	that	knowledge	is	important	because	the	data	can	therefore	be	used	 to	construct	phase	diagrams	of	APIs	 such	as	volume-against-temperature	representative	of	 the	Helmholtz	free	energy	and	the	better-known	pressure-against-temperature	representative	of	the	Gibbs	free	
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energy.	Thus,	even	if	very	little	is	known	about	the	specific	volume	of	a	given	API,	because	it	has	not	been	determined	or	cannot	be	determined	due	to	decomposition,	it	will	still	be	possible	to	determine	its	phase	behavior	and	with	it	the	stability	hierarchy	between	different	solid	phases	of	an	API.	MATERIALS	AND	METHODS	ETIFOXINE	SAMPLE	A	sample	of	racemic	etifoxine	powder	of	medicinal	grade	(D4223)	was	kindly	provided	by	Biocodex,	France.	It	was	used	as	such,	while	for	single	crystal	X-ray	diffraction	studies	suitable	crystals	were	obtained	by	slow	evaporation	from	n-hexane	solutions	at	room	temperature	(see	Figure	2).	
	
Figure	 2.	 Optical	 microscopy	 photograph	 of	 single	 crystals	 of	 racemic	 etifoxine,	 obtained	 by	 slow	evaporation	of	a	 solution	 in	n-hexane	at	 room	temperature.	The	biggest	crystals	measure	1	 to	3	mm	in	length.	SINGLE	CRYSTAL	X-RAY	DIFFRACTION.	X-ray	diffraction	intensities	were	collected	at	room	temperature	up	to	q	=	65°	(qmax)	with	an	Enraf-Nonius	CAD4	diffractometer	using	Cu-Ka	radiation	(l	=	1.54178	Å)	and	equipped	with	a	graphite	monochromator.8	Unit	cell	determination,	data	collection,	and	data	reduction	were	carried	out	with	the	CAD4	Express	Enraf-Nonius	 programs	 package	 and	 XCAD4.9	 All	 data	 were	 corrected	 for	 Lorentz	 polarization	 effects.	 The	structure	was	 solved	 by	 direct	methods	 using	 the	 SHELXS-97	package	with	which	most	 non-hydrogen	atoms	were	located.10,	11	The	remaining	atoms	were	located	after	successive	Fourier	synthesis	runs.	The	atomic	parameters	were	refined	by	a	least-squares	method	on	F2	with	SHELXL-97.10,	11	The	coordinates	of	all	non-hydrogen	atoms	were	refined	with	anisotropic	thermal	parameters.	Hydrogen	atoms	were	placed	at	calculated	positions	generated	according	to	stereochemistry	and	refined	using	a	riding	model	in	SHELXL-97.	HIGH-RESOLUTION	POWDER	X-RAY	DIFFRACTION	PXRD	 measurements	 were	 performed	 with	 a	 vertically	 mounted	 INEL	 cylindrical	 position-sensitive	detector	(CPS-120)	using	the	Debye–Scherrer	geometry	and	transmission	mode.	Monochromatic	Cu-Ka1	(l	=	1.54056	Å)	radiation	was	selected	by	means	of	an	asymmetrically	focusing	incident-beam	curved	quartz	monochromator.	Measurements	as	a	function	of	temperature	were	carried	out	using	a	liquid	nitrogen	700	series	Cryostream	Cooler	from	Oxford	Cryosystems.	Cubic	Na2Ca3Al2F4	was	used	for	external	calibration.	The	PEAKOC	application	from	DIFFRACTINEL	software	was	used	for	the	calibration	as	well	as	for	the	peak	
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position	determinations	after	pseudo-Voigt	fittings	and	lattice	parameters	were	refined	by	way	of	the	least-squares	option	of	the	FullProf	suite.12,	13	Specimens	were	introduced	in	a	Lindemann	capillary	(0.5-mm	diameter)	and	rotate	perpendicularly	to	the	X-ray	beam	during	the	experiments	to	improve	the	averaging	of	the	crystallite	orientations.	Before	each	isothermal	data	acquisition,	the	specimen	was	allowed	to	equilibrate	for	about	10	min,	and	each	acquisition	time	was	no	less	than	1	h.	The	heating	rate	in-between	data	collection	was	1.33	K	min-1.	Patterns	were	recorded	on	heating	in	the	temperature	range	from	100	K	up	to	the	melting	point.	DIFFERENTIAL	SCANNING	CALORIMETRY	(DSC)	Temperature	(onset)	and	heat	of	fusion	were	obtained	with	a	Q100	thermal	analyzer	from	TA	Instruments	at	a	10	K	min-1	heating	rate.	The	analyzer	was	calibrated	using	the	melting	point	of	indium	(Tfus	=	429.75	K	and	DfusH	=	28.45	J	g-1).	The	specimens	were	weighed	using	a	microbalance	sensitive	to	0.01	mg	and	sealed	in	aluminum	pans.	DENSITOMETRY	OF	THE	MELT	AS	A	FUNCTION	OF	TEMPERATURE	Liquid	density	as	a	function	of	temperature	was	measured	with	a	DMA-5000	Density	Meter	from	Anton-Paar.	 A	 melted	 specimen	 was	 introduced	 in	 the	 apparatus	 equilibrated	 at	 a	 temperature	 above	 the	temperature	of	 fusion.	Data	were	obtained	at	 isothermal	 steps	while	 slowly	cooling	 in	 the	 temperature	range	 from	 363	 to	 323	 K.	 Dry	 air	 and	 bi-distilled	 water	 were	 used	 as	 calibration	 standards	 in	 the	temperature	range.	The	temperature	was	controlled	at	±1	mK	and	measurements	were	performed	when	temperature	fluctuations	were	smaller	than	±	0.5	mK.	HIGH-PRESSURE	DIFFERENTIAL	THERMAL	ANALYSIS	(HP-DTA)	HP-DTA	measurements	have	been	carried	out	at	a	heating	rate	of	2	K	min-1	using	an	in-house	constructed	high-pressure	differential	thermal	analyzer	similar	to	Würflinger’s	apparatus	and	operating	in	the	298	–	473	K	and	0	–	250	MPa	ranges.14	To	determine	the	melting	temperature	as	a	function	of	pressure	and	to	ascertain	 that	 in-pan	 volumes	 were	 free	 from	 residual	 air,	 specimens	 were	 mixed	 with	 an	 inert	perfluorinated	 liquid	 (Galden®,	 from	 Bioblock	 Scientifics,	 Illkirch,	 France)	 as	 a	 pressure-transmitting	medium,	and	the	mixtures	were	sealed	into	cylindrical	tin	pans.	To	verify	that	the	perfluorinated	liquid	was	chemically	 inactive	 and	 did	 not	 interfere	 with	 the	 melting	 temperature	 of	 etifoxine,	 preliminary	 DSC	measurements	were	carried	out	with	a	Galden®-etifoxine	mixture	on	a	Q100	analyzer	of	TA	instruments	without	applied	pressure.	RESULTS	CRYSTAL	STRUCTURE	Racemic	etifoxine	was	 found	 to	be	monoclinic,	space	group	P21/n	 (n°14),	with	unit-cell	parameters	a	=	8.489(2)	Å,	b	=	17.674(2)	Å,	c	=	20.88(3)	Å,	b	=	98.86(1)°,	and	Vcell	=	3095.8(9)	Å3	at	293	K	containing	Z	=	8	molecules	per	unit-cell	and	Z’	=	2	molecules	in	the	asymmetric	unit.	The	unit	cell	is	in	accordance	with	the	unit-cell	data	published	previously.6,	7	Crystal-	and	structure-refinement	data	have	been	compiled	in	Table	
1	and	non-H	atom	coordinates	have	been	listed	in	Table	2.	Other	data	(fractional	coordinates	for	H-atoms,	bond	 lengths,	 bond	 angles,	 anisotropic	 displacement	 parameters,	 and	 torsion	 angles)	 can	 be	 found	 in	
Tables	 S1	 to	 S5	 of	 the	 Supplementary	 Information.	 The	 atom	 labelling	 is	 shown	 in	 Figure	 3.	 The	Cambridge	 Crystallographic	 Data	 Centre	 deposit	 (CCDC	 1943706)	 contains	 the	 supplementary	crystallographic	 data	 for	 this	 paper.	 It	 can	 be	 obtained	 free	 of	 charge	 from	 the	 CCDC	 via	www.ccdc.cam.ac.uk/data_request/cif.	
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Table	1.	Crystal-	and	structure-refinement	data	for	racemic	etifoxinea	Identification	code	/	Empirical	formula	 etifoxine	/	C17H17ClN2O	Formula	weight		 300.786	g	mol-1	Temperature		 293(2)	K	Wavelength		 1.5418	Å	Crystal	system	(Space	group)	 Monoclinic	(P	21/n)		Unit-cell	dimensions	 a	=	8.489(2)	Å,	b	=	17.674(2)	Å,	c	=	20.883(3)	Å,		
b	=	98.860(10)°	Cell	volume	 3095.8(9)	Å3	Z,	Z’	 8,	2	Density	(calculated)	 1.291	g/cm3	Absorption	coefficient	 2.178	mm-1	F(000)	 1264	Crystal	size	 0.550	x	0.200	x	0.100	mm3	Theta	range	for	data	collection	 3.292	to	64.944°.	Limiting	indices	 0	≤	h	≤	9,	0	≤	k	≤	20,	-24	≤	l	≤	24	Reflections	collected	/	independent	 5239	/	5239	[R(int)	=	0.0162]	Completeness	to	theta	=	64.944°	 99.9	%		Absorption	correction	 Psi-scan	Max.	and	min.	transmission	 0.9971	and	0.8015	Refinement	method	 Full-matrix	least-squares	on	F2	Data	/	restraints	/	parameters	 5239	/	0	/	382	Goodness-of-fit	on	F2	 1.131	Final	R	indices	[I>2sigma(I)]	 R1	=	0.0488,	wR2	=	0.1272	R	indices	(all	data)	 R1	=	0.0589,	wR2	=	0.1347	Extinction	coefficient	 0.0088(4)	Largest	diff.	peak	and	hole	 0.3304	and	-0.348	e.Å-3	a	esd’s	in	parentheses		
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Table	2.	Atom	coordinates	 and	equivalent	 isotropic	displacement	parameters	U(eq)	 for	 racemic	
etifoxinea	Atom	Identificationb	 x	(´	104)	 y	(´	104)	 z	(´	104)	 U(eq)c	(Å2	´	103)	Cl1_1	 6465(1)	 -3857(1)	 -2(1)	 70(1)	O1_1	 10100(2)	 -992(1)	 1252(1)	 46(1)	N1_1	 7329(2)	 -788(1)	 1138(1)	 43(1)	N2_1	 9235(2)	 147(1)	 1445(1)	 51(1)	C1_1	 9944(2)	 -1798(1)	 1358(1)	 45(1)	C2_1	 8401(2)	 -2046(1)	 953(1)	 42(1)	C3_1	 7130(2)	 -1531(1)	 902(1)	 40(1)	C4_1	 8797(2)	 -558(1)	 1281(1)	 42(1)	C5_1	 8191(3)	 -2753(1)	 667(1)	 50(1)	C6_1	 6699(3)	 -2964(1)	 356(1)	 51(1)	C7_1	 5407(3)	 -2484(1)	 332(1)	 51(1)	C8_1	 5632(3)	 -1769(1)	 600(1)	 48(1)	C9_1	 9901(2)	 -1946(1)	 2075(1)	 47(1)	C10_1	 10259(3)	 -1390(1)	 2539(1)	 60(1)	C11_1	 10199(4)	 -1536(2)	 3183(1)	 75(1)	C12_1	 9808(4)	 -2247(2)	 3373(2)	 85(1)	C13_1	 9513(4)	 -2808(2)	 2921(2)	 88(1)	C14_1	 9546(4)	 -2664(2)	 2276(1)	 71(1)	C15_1	 8156(3)	 784(1)	 1421(1)	 55(1)	C16_1	 7782(5)	 1125(2)	 776(2)	 105(1)	C17_1	 11436(3)	 -2134(2)	 1149(1)	 62(1)	Cl1_2	 3065(1)	 1044(1)	 4949(1)	 70(1)	O1_2	 5459(2)	 78(1)	 2363(1)	 48(1)	N1_2	 2674(2)	 253(1)	 2174(1)	 42(1)	N2_2	 4203(3)	 28(1)	 1358(1)	 53(1)	C1_2	 5449(2)	 -179(1)	 3024(1)	 44(1)	C2_2	 4151(2)	 258(1)	 3282(1)	 41(1)	C3_2	 2779(2)	 412(1)	 2835(1)	 39(1)	C4_2	 4022(2)	 113(1)	 1975(1)	 43(1)	C5_2	 4233(3)	 454(1)	 3928(1)	 46(1)	C6_2	 2917(3)	 780(1)	 4137(1)	 49(1)	C7_2	 1525(3)	 904(1)	 3713(1)	 50(1)	C8_2	 1458(3)	 724(1)	 3069(1)	 46(1)	C9_2	 5090(3)	 -1030(1)	 3011(1)	 46(1)	C10_2	 5444(3)	 -1480(2)	 2514(1)	 66(1)	C11_2	 5062(4)	 -2243(2)	 2495(2)	 79(1)	C12_2	 4337(4)	 -2561(2)	 2976(2)	 73(1)	C13_2	 4047(4)	 -2124(2)	 3483(2)	 73(1)	C14_2	 4418(3)	 -1361(1)	 3501(1)	 61(1)	C15_2	 2978(3)	 200(2)	 807(1)	 58(1)	C16_2	 2579(4)	 1026(2)	 744(2)	 81(1)	C17_2	 7132(3)	 -9(2)	 3364(1)	 58(1)	a	esd’s	in	parentheses	b	The	last	digit	of	the	atom	numbering	(1	or	2)	corresponds	to	either	of	molecules	1	or	2,	respectively.	c	U(eq)	is	defined	as	one	third	of	the	trace	of	the	orthogonalized	Uij	tensor.		
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Figure	3.	Molecular	structure	of	R-etifoxine	with	atom	identification.	The	hydrogen	atoms	are	labelled	with	the	same	numbers	as	the	atoms	to	which	they	are	linked.	When	more	than	one	H	is	linked	to	a	C-atom,	these	H-atoms	are	labelled	with	supplementary	letters	A,	B	and	C.	The	presented	molecule	is	2(R)	in	the	racemate	and	the	same	labelling	has	been	applied	to	molecule	1(R).	The	stereogenic	center	is	atom	C1.	THE	SPECIFIC	VOLUME	OF	RACEMIC	ETIFOXINE	AS	A	FUNCTION	OF	TEMPERATURE		An	 experimental	 and	 a	 calculated	 X-ray	 powder	 diffraction	 pattern	 are	 shown	 in	 Figure	 S1	 of	 the	supplementary	materials	 for	 comparison.	 It	 can	 be	 seen	 that	 the	 two	 patterns	 are	 virtually	 the	 same,	although	some	differences	in	peak	intensities	indicate	the	presence	of	preferred	orientation.	High	resolution	X-ray	diffraction	patterns	have	been	collected	from	100	to	340	K	to	determine	the	lattice	parameters	of	the	unit	cell	as	a	function	of	temperature	by	least-squares	refinement.	The	results	have	been	compiled	in	Table	
S6	 in	 the	 supplementary	materials.	 The	 specific	 volumes	 (v	 /cm3	g-1)	 have	 been	 fitted	 to	 the	 following	quadratic	equation	as	a	function	of	temperature	(T	/K):	
vs	=	0.74375(73)	+	4.38(71)´10-5	T	+	2.24(16)´10-7	T2	 (r2=0.9995)	 	 	 (1)	The	specific	volume	of	molten	etifoxine	from	experimental	density	measurements	have	been	reported	in	
Table	 S7	 of	 the	 supplementary	materials	 and	have	been	 fitted	as	a	 function	 of	 the	 temperature	 to	 the	following	equation:	
vliq	=	0.6359(29)	+	0.0006181(85)	T	 	 	 	 (r2	=	0.9993)	 	 	 (2)	CALORIMETRIC	BEHAVIOR	Specimens	of	the	as-received	sample	were	subjected	to	differential	scanning	calorimetry	in	closed	pans.	Heating	from	213	K	led	to	a	single	endothermic	effect	ascribed	to	a	melting	transition	with	a	mean	onset	at	362.6	±0.3	K.	The	mean	value	of	the	melting	enthalpy	was	found	to	be	85.6	±3.0	J	g-1	(25.75	±0.90	kJ	mol-1).	On	reheating	after	quick	or	slow	cooling	of	the	melt	to	213	K,	a	midpoint	glass	transition	was	observed	at	297.2	±0.8	K.	Data	from	16	experiments	have	been	compiled	in	Table	S8	of	the	supplementary	materials.	
Figure	4	contains	typical	DSC	curves,	one	for	the	crystalline	powder	and	one	for	the	glass.	
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Figure	4.		Differential	scanning	calorimetry	curves	of	racemic	monoclinic	etifoxine	obtained	at	10	K	min-1.	
(a)	First	heating	of	the	crystalline	commercial	product,	Tm:	melting	temperature,	(b)	second	heating	after	quenching	the	melt	to	213	K	in	which	a	glass	transition	(Tg:	glass	transition	temperature)	can	be	observed.	THERMAL	BEHAVIOR	UNDER	PRESSURE	A	single	endothermic	peak	of	the	fusion	of	racemic	etifoxine	was	observed	in	the	HP-DTA	experiments.	The	onset	temperature	increases	with	the	pressure	presented	in	Figure	5a	and	the	corresponding	pressure-temperature	phase	diagram	is	depicted	in	Figure	5b.	The	onset	temperatures	(T	/K)	of	the	melting	peaks	and	the	corresponding	pressures	(P	/MPa)	listed	in	Table	S9	in	the	supplementary	materials	have	been	fitted	to	the	quadratic	equation:	
P	=	885(324)	-7.95(1.65)	T	+	0.0152(21)	T2	 	 (r2	=	0.9992)	 	 	 (3)	
	
Figure	5.	(a)	Melting	peaks	of	racemic	etifoxine	at	various	pressures	and	(b)	 the	pressure-temperature	phase	diagram		 	
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DISCUSSION	CRYSTAL	STRUCTURE	The	centrosymmetric	unit-cell	of	racemic	etifoxine	contains	two	independent	molecules	numbered	1	and	2	whose	3D	projection	is	shown	in	Figure	6.	
	
Figure	6.	Monoclinic	unit-cell	of	racemic	etifoxine	with	the	two	independent	molecules	1	(red)	and	2	(blue).		The	two	independent	molecules	mainly	differ	in	the	orientations	of	the	phenyl	rings	j1	with	respect	to	the	heterocycles	 (see	Figure	7):	 the	 values	 of	 the	 dihedral	 angles	 C2-C1-C9-C14	 are	 53.95°	 and	 -37.88°	 in	molecules	1	and	2,	respectively.	Weak	intramolecular	interactions	prevent	the	rotation	of	the	two	NH-CH2-CH3	chains	around	the	N2-C4	bonds:	N2-H2_1···O1_1	is	2.250	Å,	and	N2-H2_2···O1_2	equals	2.239	Å,	as	well	as	the	rotation	of	the	two	phenyl	rings	j1	around	the	C1-C9	bonds:	C10-H10_1···O1_1	is	2.404	Å	and	C10-H10_2···O1_2	equals	2.454	Å.	The	molecules	are	held	 together	by	N1···H-N2	hydrogen	bonds	 that	 form	infinite	chains	parallel	to	the	a	axis	and	to	the	ac	plane	(see	supplementary	materials	Figure	S2).	These	interactions,	 in	 addition	 to	 the	 weak	 C-H···O	 interactions	 have	 been	 compiled	 in	 Table	 S10	 in	 the	supplementary	materials.		
	
Figure	7.	Superposition	showing	the	difference	in	conformation	of	molecules	1	(red)	and	2	(blue)	
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THERMAL	EXPANSION	OF	THE	SOLID	AND	THE	LIQUID	Although	 the	 thermal	 expansion	 of	 the	 solid	 is	 best	 fitted	 by	 a	 quadratic	 equation	 (eq.	 1),	 it	 can	 be	approximated	by	a	linear	expression:	
vs(T)	=	0.7343(11)	+	0.0001426(46)	T	 	 	 (r2	=	0.9887)	 	 	 (4).	An	average	expansivity	of	the	solid	av,s	of	1.94	´	10-4	K-1	can	be	obtained	by	rewriting	eq.	4	in	the	form	of	
vs(T)	=	v0	´	(1+av,s	T).	This	solid	expansivity	is	very	close	to	the	mean	value	for	molecular	organic	solids	of	2.21	´	10-4	K-1	that	has	been	reported	previously.15-17	The	expansivity	of	liquid	etifoxine	is	found	to	be	0.97	´10-3	K-1	obtained	from	eq.	2.	This	is	smaller	than	the	mean	value	of	1.20	±0.25	´10-3	K-1	found	previously	for	the	expansivity	of	molten	active	pharmaceutical	ingredients;16,	17	however,	it	still	falls	within	the	range	of	experimental	uncertainty	of	0.25	´10-3	K-1.	VOLUME	CHANGE	ON	MELTING	AND	VOLUME	DIFFERENCE	AT	THE	GLASS	TRANSITION	It	has	been	previously	 reported	 that,	 in	 the	case	of	molecular	organic	 solids,	 the	change	 in	 the	specific	volume	on	melting	 is	about	 11	±3	%,16-18	 i.e.	 slightly	 smaller	 than	 the	 12	%	value	 found	previously	 by	Goodman	et	al.19	Calculating	the	specific	volumes	of	the	solid	and	of	the	liquid	using	eqs.	1	and	2	at	Tfus	=	362.6	K,	it	is	found	that	the	volume	change	on	melting	is	in	the	present	case	0.0709	cm3	g-1,	leading	to	the	value	of	1.090	±0.010	for	the	vliq/vs	ratio	at	Tfus,	in	fair	agreement	with	the	above-mentioned	value.	At	the	glass	transition,	the	metastable	undercooled	melt	rigidifies,	i.e.	becomes	as	viscous	as	the	crystalline	solid.	The	glass	transition	temperature	has	been	found	at	297.2	K	(10	K	min-1).		The	specific	volume	of	the	melt	at	Tg	can	be	calculated	with	eq.	2	and	is	found	to	be	0.8196	cm3	g-1,	while	that	of	the	crystalline	solid	at	this	temperature	is	0.7766	cm3	g-1	from	eq.	1.	Thus,	the	ratio	vglass/vs	at	Tg	equals	1.055	±0.010,	i.e.	the	volume	 difference	 between	 the	 crystalline	 and	 the	 amorphous	 phase	 is	 approximately	 half	 that	 of	 the	difference	at	the	melting	point.	With	this	information,	one	can	draw	the	temperature	-	(specific)	volume	diagram,	shown	in	Figure	8,	which	is	a	partial	projection	of		F(v,T),	the	Helmholtz	function	of	the	system,	on	a	T-v	plane,	one	of	the	four	thermodynamically	equivalent	energy	functions	of	the	system.	vglass/vs	ratios	have	been	found	for	other	cases,	which	have	been	compiled	in	Table	3.	
	
Figure	 8.	 Specific	 volumes	 of	 solid	 (S)	 and	 liquid	 (L)	 etifoxine	 as	 a	 function	 of	 temperature	 with	extrapolation	to	the	Kauzmann	temperature	Tk	=	204.6	K	using	eqs.	1	and	2.		
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Table	 3.	 Experimental	 volume	 changes	 for	 molecular	 compounds	 and	 pharmaceuticals	 at	 their	
melting	point	and	glass	transition	temperature	compound	 vL/vI	at	Tfus	 Tfus/K	 vL/vI	at	Tg	 Tg	/K	 Tg/Tfus	 Reference	paracetamol	 1.15	 442.3	 1.07	 298	 0.673	 20	prilocaine	 1.13	 311.5	 1.07	 218	 0.700	 21	rimonabant	 1.11	 429.2	 1.04	 350	 0.820	 22	biclotymol	 1.13	 400.5	 1.05	 294	 0.734	 23	ternidazole	 1.11	 333.0	 1.07	 235	 0.706	 24	morniflumate	 1.12	 348.1	 1.06	 249	 0.715	 18	etifoxine	 1.09	 362.4	 1.055	 297.2	 0.820	 This	work	Mean	 1.12(2)	 	 1.06(1)	 	 	 	SLOPE	OF	THE	SOLID-LIQUID	EQUILIBRIUM	IN	THE	PRESSURE-TEMPERATURE	DIAGRAM	Using	eq.	3,	it	is	found	that	the	slope	of	the	melting	equilibrium	of	racemic	etifoxine	at	P	=	0	MPa	equals	3.29	±0.06	MPa	K-1	(Figure	5b).	This	slope	can	also	be	determined	through	the	Clapeyron	equation	dP/dT	=	
DfusH/(Tfus	Dv)	in	which	DfusH	is	the	melting	enthalpy	(85.60	J	g-1),	Tfus	the	melting	temperature	(362.6	K),	and	Dv	the	volume	change	on	melting	(0.07094	cm3	g-1).	With	these	experimental	values,	the	value	of	dP/dT	is	 found	 to	be	3.33	±0.12	MPa	K-1,	 i.e.	extremely	close	 to	 the	direct	experimental	value	of	3.29	MPa	K-1,	indicating	 that	 at	 least	 in	 the	 case	 of	 etifoxine,	 the	 Clapeyron	 equation	 is	 a	 good	 alternative	 for	 direct	measurements	to	obtain	the	response	of	the	system	to	pressure.	ISOBARIC	THERMAL	EXPANSION	TENSOR	FOR	THE	SOLID	The	anisotropy	of	the	intermolecular	interactions	can	be	accounted	for	by	the	isobaric	thermal	expansion	tensor,	which	shows	the	influence	of	these	interactions	in	the	crystal	on	heating.25	The	eigenvalues	and	the	eigenvectors	 of	 the	 tensor	 specify	 the	 strongest	 and	 the	 weakest	 directions	 for	 the	 intermolecular	interactions,	commonly	referred	to	as	“hard”	and	“soft”	directions,	respectively.25	The	lattice	parameters	as	a	function	of	temperature	have	been	determined	(see	supplementary	materials,	
Table	S6)	and	fitted	using	the	least-squares	method.	The	coefficients	of	the	related	polynomial	equations	have	 been	 compiled	 in	Table	 S11	 in	 the	 supplementary	materials,	 together	with	 the	 reliability	 factor,	defined	as	R=S(yoi	-	yci)2/yci2,	where	yoi	and	yci	are	the	measured	and	calculated	lattice	constants,	respectively.	The	procedure	to	determine	the	eigenvalues	and	eigenvectors	of	the	second-rank	aij	 thermal	expansion	tensor	 has	 been	 detailed	 previously.25	 For	 monoclinic	 symmetry,	 the	 tensor	 is	 fully	 defined	 by	 three	eigenvalues	ai	(i	=	1,2,3)	and	by	an	angle	between	the	direction	of	one	of	the	eigenvectors	(a1	in	the	present	case)	and	the	crystallographic	axis	a,	the	a2	direction	being	parallel	to	the	two-fold	axis	b.	Figure	9	depicts	the	variation	of	the	eigenvalues	of	the	thermal-expansion	tensor	as	a	function	of	temperature	as	well	as	the	3D-tensor	within	the	orthogonal	frame	of	eigenvectors	together	with	the	crystallographic	axes	at	140	K.	The	tensor	is	rather	anisotropic	and	this	anisotropy	increases	with	temperature.	The	thermal	expansion	within	the	ab	plane	is	the	highest	(“soft”	plane)	while	the	lowest	deformation	(a3	direction)	corresponding	to	a	“hard	direction”	is	found	within	the	ac	plane	as	a	consequence	of	the	intermolecular	hydrogen	bonding	(N2-H···N1).	
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Figure	 9.	ai	 eigenvalues	 of	 the	 thermal-expansion	 tensor	 as	 a	 function	 of	 temperature	 for	 the	 P21/n	monoclinic	phase	of	etifoxine	with	the	a2	eigenvector	parallel	to	the	two-fold	crystallographic	axis	b,	as	evidenced	 in	 the	 tensor	 representation	 at	 140	 K	 in	 the	 inset	 (full	 length	 scale	 of	 the	ai	 eigenvectors	corresponds	to	10-4	K-1).	CONCLUDING	REMARKS	The	crystal	 structure	of	 racemic	etifoxine	has	been	solved	at	 room	temperature	and	 thermal	expansion	studies	in	the	range	from	100	K	to	340	K	as	well	as	differential	scanning	calorimetry	did	not	reveal	any	crystalline	polymorphism.	However	the	crystal	structure	contains	two	independent	molecules	(Z’	=	2)	with	different	conformations,	which	implies	a	possibility	for	etifoxine	to	exhibit	conformational	polymorphism	as	previously	defined	by	Bernstein	and	Hagler.26	It	has	been	shown	that	the	thermal	expansion	of	etifoxine	is	very	similar	to	that	of	small	organic	molecules	in	general,	for	the	solid	as	well	as	for	the	liquid.	As	far	as	the	volume	change	on	melting	is	concerned,	it	has	been	found	that,	again	in	the	present	case,	it	agrees	with	the	average	value	of	11%	within	an	error	of	less	than	 3%.	 In	 addition,	 the	 volume	 difference	 between	 the	 crystal	 and	 the	 metastable	 liquid	 at	 the	temperature	of	the	glass	transition	is	found	to	be	about	6	%,	in	close	accordance	with	previously	found	data.	Further	case	studies	are	still	needed	before	one	can	conclude	 that	 these	volume	changes	 for	molecular	organic	compounds	are	more	or	less	independent	of	the	chemical	composition	and	thus	‘statistically’	and	possibly	in	a	deeper	sense	universal.	
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